Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Boehringer Ingelheim
Johnson and Johnson
Colorcon
Dow

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR TOLCAPONE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Tolcapone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00033059 ↗ Assessment of Potential Interactions Between Cocaine and Tolcapone - 1 Unknown status National Institute on Drug Abuse (NIDA) Phase 1 2001-07-01 The purpose of this study is to assess the potential interactions between intravenous (IV) cocaine and tolcapone.
NCT00044083 ↗ Clinical Trial of Tolcapone for Cognition in Schizophrenia Terminated National Institute of Mental Health (NIMH) Phase 2 2002-08-01 This study will evaluate whether Tolcapone improves cognition in healthy volunteers as well as patients with schizophrenia. Talcapone is a drug that has been FDA approved for Attention Deficit Disorder and allegedly increase the amount of the neurotransmitter dopamine in the frontal cortex of the brain. ...
NCT00548327 ↗ The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype Terminated National Institute of Mental Health (NIMH) Phase 2 2007-10-01 This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Atomoxetine is a drug that has been Food and Drug Administration (FDA) approved for Attention Deficit Disorder and allegedly increase the amount of the neurotransmitter dopamine in the frontal cortex of the brain.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tolcapone

Condition Name

Condition Name for Tolcapone
Intervention Trials
Nicotine Dependence 2
Obsessive-Compulsive Disorder 2
Alcohol Use Disorder 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tolcapone
Intervention Trials
Tobacco Use Disorder 3
Disease 3
Alcoholism 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tolcapone

Trials by Country

Trials by Country for Tolcapone
Location Trials
United States 28
Germany 1
Switzerland 1
Sweden 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tolcapone
Location Trials
California 7
Pennsylvania 3
Maryland 3
South Carolina 3
Connecticut 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tolcapone

Clinical Trial Phase

Clinical Trial Phase for Tolcapone
Clinical Trial Phase Trials
Phase 4 3
Phase 2/Phase 3 1
Phase 2 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tolcapone
Clinical Trial Phase Trials
Completed 17
Terminated 3
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tolcapone

Sponsor Name

Sponsor Name for Tolcapone
Sponsor Trials
University of California, San Francisco 7
University of California, Berkeley 5
National Institute on Drug Abuse (NIDA) 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tolcapone
Sponsor Trials
Other 34
NIH 8
U.S. Fed 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
AstraZeneca
Colorcon
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.